KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBITDA: 2009-2025

Historic EBITDA for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $57.5 million.

  • Jazz Pharmaceuticals' EBITDA fell 77.90% to $57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $452.6 million, marking a year-over-year decrease of 30.19%. This contributed to the annual value of $716.6 million for FY2024, which is 23.86% up from last year.
  • Jazz Pharmaceuticals' EBITDA amounted to $57.5 million in Q3 2025, which was up 202.89% from -$55.9 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year EBITDA high stood at $260.2 million for Q3 2024, and its period low was -$263.4 million during Q4 2022.
  • Its 3-year average for EBITDA is $129.7 million, with a median of $141.8 million in 2023.
  • In the last 5 years, Jazz Pharmaceuticals' EBITDA slumped by 633.39% in 2022 and then surged by 596.17% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' EBITDA (Quarterly) stood at $49.4 million in 2021, then plummeted by 633.39% to -$263.4 million in 2022, then surged by 146.51% to $122.5 million in 2023, then skyrocketed by 55.73% to $190.8 million in 2024, then slumped by 77.90% to $57.5 million in 2025.
  • Its last three reported values are $57.5 million in Q3 2025, -$55.9 million for Q2 2025, and $190.8 million during Q4 2024.